Combination Immunotherapy in Non-small Cell Lung Cancer

Combination Immunotherapy in Non-small Cell Lung Cancer Purpose of Review Checkpoint blockade has changed the treatment landscape in non-small cell lung cancer (NSCLC), but single-agent approaches are effective for only a select subset of patients. Here, we will review the evidence for combination immunotherapies in NSCLC and the clinical data evaluating the efficacy of this approach. Recent Findings Clinical trials evaluating combination PD-1 and CTLA-4 blockade as well as PD-1 in combination with agents targeting IDO1, B7-H3, VEGF, and EGFR show promising results. Additional studies targeting other immune pathways like TIGIT, LAG-3, and cellular therapies are ongoing. Summary Combination immunotherapy has the potential to improve outcomes in NSCLC. Data from early clinical trials is promising and reveals that these agents can be administered together safely without a significant increase in toxicity. Further studies are needed to evaluate their long-term safety and efficacy and to determine appropriate patient selection. . . . . . Keywords NSCLC Combination immunotherapy Checkpoint inhibitors CTLA-4 PD-1 PD-L1 Introduction immunotherapy was seen in the first-line treatment-naïve set- ting. In a selected population of patients with high PD-L1 The success of single-agent checkpoint blockade has trans- expression (PD-L1 ≥ 50%), pembrolizumab was associated formed the treatment paradigm of advanced-stage non-small with a 44.8% http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Oncology Reports Springer Journals

Combination Immunotherapy in Non-small Cell Lung Cancer

Loading next page...
 
/lp/springer_journal/combination-immunotherapy-in-non-small-cell-lung-cancer-NC0jzTiAQb
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer Science+Business Media, LLC, part of Springer Nature
Subject
Medicine & Public Health; Oncology
ISSN
1523-3790
eISSN
1534-6269
D.O.I.
10.1007/s11912-018-0697-7
Publisher site
See Article on Publisher Site

Abstract

Purpose of Review Checkpoint blockade has changed the treatment landscape in non-small cell lung cancer (NSCLC), but single-agent approaches are effective for only a select subset of patients. Here, we will review the evidence for combination immunotherapies in NSCLC and the clinical data evaluating the efficacy of this approach. Recent Findings Clinical trials evaluating combination PD-1 and CTLA-4 blockade as well as PD-1 in combination with agents targeting IDO1, B7-H3, VEGF, and EGFR show promising results. Additional studies targeting other immune pathways like TIGIT, LAG-3, and cellular therapies are ongoing. Summary Combination immunotherapy has the potential to improve outcomes in NSCLC. Data from early clinical trials is promising and reveals that these agents can be administered together safely without a significant increase in toxicity. Further studies are needed to evaluate their long-term safety and efficacy and to determine appropriate patient selection. . . . . . Keywords NSCLC Combination immunotherapy Checkpoint inhibitors CTLA-4 PD-1 PD-L1 Introduction immunotherapy was seen in the first-line treatment-naïve set- ting. In a selected population of patients with high PD-L1 The success of single-agent checkpoint blockade has trans- expression (PD-L1 ≥ 50%), pembrolizumab was associated formed the treatment paradigm of advanced-stage non-small with a 44.8%

Journal

Current Oncology ReportsSpringer Journals

Published: May 8, 2018

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off